Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> Bacteremia

202393 citationsJournal Article

Authors

Thomas L Holland · Johns Hopkins University

Sara E. Cosgrove · Johns Hopkins University

Sarah B. Doernberg · Johns Hopkins University

Timothy C Jenkins · Johns Hopkins University

Nicholas Turner · Johns Hopkins University

Helen W. Boucher · Tufts University

Oleksander Pavlov ·

Abstract

Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated <i>S. aureus</i> bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.).

Topics & Keywords

Antimicrobial Resistance in Staphylococcus Infective Endocarditis Diagnosis and Management Bacterial Identification and Susceptibility Testing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 15, pp. 1390-1401

DOI: 10.1056/nejmoa2300220

Field-Weighted Citation Impact: 17.99